ASCO-GU – Arvinas sees the path to a prostate cancer niche

The good news for Arvinas is that ARV-110, an asset some had virtually written off, might arguably have legs. The bad is that its opportunity will probably be limited to a small, genetically defined population of late-stage prostate cancer patients.